Market Overview

UPDATE: Goldman Sachs Upgrades Stryker Corporation to Buy on Organic Growth, Capital Allocation

Related SYK
The Top 25 Analysts On Wall Street
Stryker Release Confirms Settlement Deal Related to Orthopaedics Unit, Has Recorded $1.425B in Charges
Google Leads Funding in Virtual Reality Startup (Fox Business)

Goldman Sachs raised its rating on Stryker Corporation (NYSE: SYK) from Neutral to Buy and increased its price target from $55 to $68.

Goldman Sachs noted, "Our thesis calls for improvements in both operational and financial performance as follows: (1) new CEO and a reset of expectations for 2013; (2) strong product portfolio/pipeline and diversified revenue base offer multiple growth opportunities; (3) shareholder-friendly capital allocation with a greater orientation to cash returns; (4) cost and quality control initiatives remain a source of margin opportunity; and (5) attractive relative valuation compared to other large-cap MedTech firms in our coverage universe."

Stryker Corporation closed at $54.57 on Monday.

Latest Ratings for SYK

DateFirmActionFromTo
Oct 2014Canaccord GenuityMaintainsBuy
Aug 2014NeedhamUpgradesBuy
Jul 2014CitigroupMaintainsNeutral

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (SYK)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional